W
eight gain is a serious problem with numerous psychotropic drugs (1) , and drug-induced weight gain may be associated with health risks typically linked to obesity such as type 2 diabetes. Some second generation antipsychotics are known to lead to weight gain and to impair glucose tolerance (2), but little is known about the influence of weight gain-inducing novel antidepressants such as mirtazapine on glucose tolerance.
In a naturalistic study, we assessed weight, glucose tolerance, and plasma levels of insulin and cortisol, which are major players regarding glucose metabolism (3), in 11 inpatients (7 males and 4 females; age [mean Ϯ SD]: 46.7 Ϯ 20.5 years; weight: 73.3 Ϯ 5.5 kg) with major depression according to the ICD-10 and Diagnostic and Statistical Manual of Mental Disorders Fourth Edition receiving mirtazapine during psychiatric hospital treatment of 2-6 weeks. After the initial baseline examination, mirtazapine treatment was started and the dosage adjusted according to clinical needs. At baseline and at the end of treatment, patients were weighed and underwent an oral glucose tolerance test (OGTT) over 4 h.
During treatment with mirtazapine, subjects gained on average 2.17 Ϯ 1.97 kg (t ϭ 3.65, df ϭ 10, P ϭ 0.004). However, basal serum glucose (102 Ϯ 14 vs. 96 Ϯ 6 mg/dl; t ϭ 2.23, df ϭ 10, P ϭ 0.05) and glucose tolerance as measured by 120-min glucose (150 Ϯ 83 vs. 128 Ϯ 83 mg/dl; t ϭ 2.25, df ϭ 10, P ϭ 0.048) and glucose area under the curve during OGTT (df ϭ 10, P ϭ 0.028) improved in parallel. Also, 120-min insulin levels decreased during treatment (from 51 Ϯ 27 to 37 Ϯ 34 U/ml; t ϭ 2.33, df ϭ 10, P ϭ 0.042). Indexes of insulin sensitivity (4) showed no statistically significant changes during the treatment period (homeostasis model assessment: from 4.91 Ϯ 1.44 to 5.01 Ϯ 1.19; t ϭ Ϫ0.22, df ϭ 10, P ϭ 0.827; Matsuda and DeFronzo index: from 4.42 Ϯ 1.71 to 4.89 Ϯ 2.12, t ϭ Ϫ1.00, df ϭ 10, P ϭ 0.339). Cortisol levels did not decrease significantly from baseline to the end of therapy but did between baseline and treatment week 2 (from 195.11 Ϯ 58.29 to 162.98 Ϯ 34.54 g/l; t ϭ 2.28, df ϭ 9, P ϭ 0.049).
The present study confirms that treatment with mirtazapine is likely to be associated with weight gain. Although weight gain is expected to impair glucose tolerance, mirtazapine had the opposite effect in the present study.
Improved glucose tolerance during treatment with mirtazapine may, at least in part, be mediated by a reduction of cortisol secretion, because cortisol plasma levels are reported to be elevated in depressed patients (5), and it was found that they can be lowered by antidepressant treatment with mirtazapine (6) .
Usually, depression goes along with a decrease in physical activity, appetite, and food intake but a relative excess of carbohydrates and a preference for sweets (7) . Recovery from depression might therefore lead to favorable changes in nutritional preferences and physical activity. Additionally, mirtazapine unfolds ␣-adrenergic antagonism effects by blocking ␣ 2 -receptors (8). It is possible that this ␣-adrenergic antagonism is responsible for the drop in glucose, similar to the effect of the ␣-adrenergic antagonist doxazosin, which has been reported to lead to a decrease in plasma glucose during OGTT without changing the plasma insulin response (9).
Depression has been significantly linked with the development of type 2 diabetes (10), making it highly desirable to gain further knowledge on the effect of antidepressants on glucose metabolism. labeling (1,2) . Four studies have previously found that metformin is commonly prescribed, despite risk factors, with a range of 24.5-54% in outpatients and 64 -73% in inpatients (3, (5) (6) (7) . The purpose of our study was to determine the frequency of inappropriate prescribing of metformin to patients with precautions or contraindications at an academic health center and secondarily to compare the findings with previously published studies.
HUBERTUS HIMMERICH
This retrospective study was approved by the institutional review board of the University of Michigan. We performed a chart review where 100 inpatients and 103 outpatients were randomly selected from 300 patients who received metformin between January and June of 2003. Patients' medical records were used to collect demographic data, clinical characteristics, laboratory parameters, and information about contraindications and precautionary conditions. Risk factors for MALA were identified through ICD-9 codes in the clinical data repository, laboratory tests, and medical notes.
A power analysis estimated that a sample size of 78 patients in each group was sufficient to detect a 20% difference in the frequency of inappropriate prescribing compared with the frequency (73%) reported by Holstein et al. (␣ ϭ 0.05, ␤ ϭ 0.8) (3). A sample size of 100 patients per group was selected for simplicity. Frequencies of inappropriate prescribing were compared with literaturereported rates using Fisher's exact test (4) . Inpatient results were compared with those of Calabrese et al. (5) . Outpatient results were compared with those of Emslie-Smith et al. (6) .
Of 103 outpatients, 3 (2.9%) had contraindications to metformin use. This is significantly lower than the 24.5% incidence of contraindications reported by Emslie-Smith et al. (P ϭ 0.0001) (6) . The contraindication present in all three of these patients was congestive heart failure requiring drug therapy.
Of 100 inpatients, 68 (68%) had contraindications or precautionary conditions to metformin use. This incidence of inappropriate prescribing is not significantly different (P ϭ 0.2524) from the results of Calabrese et al., who found a similar incidence of 62% of inpatients receiving metformin. In our inpatient sample, the most commonly seen precautions were concomitant cationic drug use and failure to measure serum creatinine before restarting metformin after a surgical procedure. No cases of metabolic acidosis were documented. Approximately 25% of inpatients had more than one precautionary or contraindicating condition; however, there were no patients with more than three risk factors.
We have demonstrated that in our health system, prescribing patterns do not conform to the guidelines established by the manufacturer and the Food and Drug Administration. While the incidence of inappropriate prescribing for outpatients is lower than that reported in the literature, inappropriate use of metformin among inpatients is frequent and occurs at a rate similar to that reported in the literature. Frequent metformin use in patients with risk factors was not accompanied by lactic acidosis in our population. Reexamination of these precautionary and contraindicating conditions in light of extensive worldwide experience with metformin could be helpful in more precisely identifying patients who are likely to develop MALA. This would minimize unnecessary avoidance of the drug in patients with type 2 diabetes who could benefit from treatment. 
